These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17265022)

  • 41. Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells.
    Daguzan C; Moulin M; Kulyk-Barbier H; Davrinche C; Peyrottes S; Champagne E
    J Immunol; 2016 Mar; 196(5):2219-29. PubMed ID: 26819204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines.
    Cimini E; Piacentini P; Sacchi A; Gioia C; Leone S; Lauro GM; Martini F; Agrati C
    Int J Immunopathol Pharmacol; 2011; 24(1):139-48. PubMed ID: 21496396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
    Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
    Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
    Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
    Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
    Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
    Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8
    Chen HC; Joalland N; Bridgeman JS; Alchami FS; Jarry U; Khan MWA; Piggott L; Shanneik Y; Li J; Herold MJ; Herrmann T; Price DA; Gallimore AM; Clarkson RW; Scotet E; Moser B; Eberl M
    Immunol Cell Biol; 2017 Aug; 95(7):620-629. PubMed ID: 28356569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-fibrotic characteristics of Vγ9+ γδ T cells in systemic sclerosis.
    Markovits N; Bendersky A; Loebstein R; Brusel M; Kessler E; Bank I
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):23-29. PubMed ID: 26886502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.
    Thedrez A; Lavoué V; Dessarthe B; Daniel P; Henno S; Jaffre I; Levêque J; Catros V; Cabillic F
    PLoS One; 2013; 8(5):e63322. PubMed ID: 23717410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
    Casetti R; Perretta G; Taglioni A; Mattei M; Colizzi V; Dieli F; D'Offizi G; Malkovsky M; Poccia F
    J Immunol; 2005 Aug; 175(3):1593-8. PubMed ID: 16034098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
    Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
    J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet.
    Aehnlich P; Carnaz Simões AM; Skadborg SK; Holmen Olofsson G; Thor Straten P
    Front Immunol; 2020; 11():1868. PubMed ID: 32983105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
    Kabelitz D; Wesch D; Pitters E; Zöller M
    J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
    Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
    Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Central memory Vgamma9Vdelta2 T lymphocytes primed and expanded by bacillus Calmette-Guérin-infected dendritic cells kill mycobacterial-infected monocytes.
    Martino A; Casetti R; Sacchi A; Poccia F
    J Immunol; 2007 Sep; 179(5):3057-64. PubMed ID: 17709520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells.
    Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
    Anticancer Res; 2020 Sep; 40(9):5221-5227. PubMed ID: 32878810
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer.
    Laplagne C; Meddour S; Figarol S; Michelas M; Calvayrac O; Favre G; Laurent C; Fournié JJ; Cabantous S; Poupot M
    Front Immunol; 2020; 11():1396. PubMed ID: 32733462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.